# Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

> **NCT06500273** · PHASE2 · RECRUITING · sponsor: **Allogene Therapeutics** · enrollment: 250 (estimated)

## Conditions studied

- Large B-cell Lymphoma

## Interventions

- **GENETIC:** cemacabtagene ansegedleucel
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DEVICE:** Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

## Key facts

- **NCT ID:** NCT06500273
- **Lead sponsor:** Allogene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-18
- **Primary completion:** 2027-12
- **Final completion:** 2032-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500273, "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06500273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*